Annals of internal medicine
-
Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19). ⋯ U.S. Department of Veterans Affairs.
-
Identifying occupational risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs) can improve HCW and patient safety. ⋯ Emory COVID-19 Response Collaborative.
-
Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting autoimmune disease (AID) have been excluded from clinical trials. ⋯ The Netherlands Organization for Health Research and Development.
-
Comment
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22-31. 33338413.
-
Favresse J, Gillot C, Oliveira M, et al. Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection. J Clin Med. 2021;10:265. 33450853.